Browsing ODA Open Digital Archive by Subject "177Lu-lilotomab satetraxetan"
Now showing items 1-1 of 1
-
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
(European Journal of Nuclear Medicine and Molecular Imaging;July 2018, Volume 45, Issue 7, Journal article; Peer reviewed, 2018-02-22)Purpose: 177Lu-lilotomab satetraxetan is a novel anti-CD37 antibody radionuclide conjugate for the treatment of non-Hodgkin lymphoma (NHL). Four arms with different combinations of pre-dosing and pre-treatment have been ...